Ignite Creation Date:
2024-05-05 @ 9:27 PM
Last Modification Date:
2024-10-26 @ 10:04 AM
Study NCT ID:
NCT00887718
Status:
COMPLETED
Last Update Posted:
2012-12-18
First Post:
2009-04-23
Brief Title:
Positron Emission TomographyPET in Lymphoma Assessment
Sponsor:
University Health Network Toronto
Organization:
University Health Network Toronto
Study Overview
Official Title:
Positron Emission Tomography for Staging and Treatment Assessment of Response in Lymphomas the Pet-star Lymphoma Study
Status:
COMPLETED
Status Verified Date:
2012-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study examines the role of a diagnostic test called Positron Emission Tomography PET scanning in patients with malignant lymphoma The primary goal of this study is to find out how well PET scanning can detect malignant cancerous lymphoma and how often this extra information will result in a change of stage of disease or will result in a change in treatment management plans of patients with lymphoma
Detailed Description:
It is currently unknown whether modifying treatment based on FDG-PET results is appropriate However clinicians are increasingly using the FDG-PET result where obtained in deciding management Consequently it would be premature to mandate PET-based treatment modifications in this protocol Patients will be treated with existing protocols at the discretion of their treating oncologists based on available information Oncologists will be surveyed as to whether FDG-PET scan results could have or affect patient management and the intervention will be recorded
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None